U.S., Dec. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07274241) titled 'Escitalopram and the Risk of Serious Adverse Events' on Nov. 27.
Brief Summary: The goal of this population-based cohort study is to assess the safety of initiating a new outpatient prescription of 10mg/day of Escitalopram (higher dose) compared to 5 mg/day (lower dose) in adults over the age of 65 with low kidney function.
Primary question
Whether initiating a new outpatient prescription of a higher dose of Escitalopram (10mg/day) compared to a lower dose (5 mg/day) in older adults with low kidney function (an eGFR <45 mL/min per 1.73 m2 but not receiving dialysis or having a history of kidney transplantation) is associated with ...